

Terapio Achievements Highlighted at NIH National Institute of Allergy and Infectious Diseases Advisory Council

Austin, Texas, January 28, 2014 — The annual meeting of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Advisory Council was held on January 27, 2014. The Division of Allergy, Immunology, and Transplantation (DAIT) subcommittee was presented with highlights of the Small Business Innovative Research (SBIR) program. Terapio's radiation countermeasure program was selected to showcase the Company's success in leveraging other NIH programs available to SBIR awardees.

In addition to being awarded Phase I and Phase II SBIR grants, other programs for which Terapio has been selected include:

- The DAIT Radiation/Nuclear Countermeasures Product Development Program which has completed two successful nonclinical studies at Indiana University through the Product Development Support Services Contract to test the efficacy of RLIP76-PL as a radiation countermeasure;
- The NIH Commercialization Assistance Program which provided Terapio expert advice on a regulatory strategy under the FDA's Animal Rule; and, most recently,
- The Bridging Interventional Development Gaps (BrIDGs) program, which is co-funded by NIAID and the NIH's National Center for Advancing Translational Sciences (NCATS), which will provide support for cGMP manufacturing organizations to produce RLIP76-PL for preclinical therapeutic development.

About Terapio Corporation

Terapio is a biopharmaceutical company developing therapeutics based on the RLIP76 protein. Initial applications include developing the RLIP76 protein as a medical countermeasure for radiation exposure and chemical threats to civilian, military, and first responder populations faced with emergencies from terrorist acts or industrial accidents. Terapio is also developing the protein to aid patients in recovery from traumatic brain injury and stroke. The RLIP76 protein primarily works through the oxidative stress pathway and provides benefit as both a prophylactic and post event treatment. Terapio's key innovation was the discovery that RLIP76 protein could be administered exogenously when encapsulated in liposomes and reach many of the body's organs quickly, increasing the transport capacity of the cells of those organs and allowing them to deal with toxins associated with oxidative stress, which has found to be prevalent in the recovery phase of traumatic brain injury and stroke patients.

About Acute Radiation Syndrome (ARS)

ARS, or radiation sickness, is an acute illness caused by exposure of all or part of the body to a high dose of penetrating radiation in a very short period of time. The dose and length of exposure determines the extent of organ systems affected and ultimately, the potential lethality threat to the patient. The hematopoietic (bone marrow) syndrome of ARS will occur at lower radiation doses and while some cases will recover, there is a greater risk of death without treatment as the radiation dose level increases. The primary cause of death



is the destruction of the bone marrow, resulting in infection and hemorrhage. Higher dose result in damage to the gastrointestinal tract and central nervous system where mortality is almost always 100% in these cases.

CONTACT: Terapio Corporation
Curt Bilby
President and CEO
1-512-697-8179
contact.terapio@terapio.com